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Richard Stephens1* and David Stewart2Abstract
As the enthusiasm for individualized treatment and targeted therapies continues to gain momentum, it seems
timely to re-assess whether our current research tools are fit for purpose. Randomized Clinical Trials compare groups
of patients, the Hazard Ratio is a ‘group summary statistic’, and modeling shows that the same Hazard Ratio score
could result from a number of scenarios. Thus the current tools do not provide definitive information as to how to
treat an individual patient. We therefore need to concentrate on the use of predictive factor analyses to identify the
characteristics of subgroups of patients who respond to specific treatments.
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analysesBackground
Ever since the first trials of streptomycin for tuberculosis
in the 1940’s, the randomized clinical trial (RCT) has
been regarded as the gold standard method for assessing
new treatments. Similarly, for RCTs with time-to-event
outcomes such as survival or progression-free survival,
the widely accepted summary statistic to compare treat-
ment arms is the Hazard Ratio (HR), which essentially
compares the areas under the survival curves for the 2
treatments. Nevertheless, it is easy to forget that RCTs
compare groups of patients, and that the HR is a ‘group
summary statistic’ and thus neither RCTs nor HRs pro-
vides definitive information as to how to treat an indi-
vidual patient.Discussion
While quality of life, toxicity and cost are often accepted
as important secondary outcomes, the common assump-
tion in most cancer RCTs seems to be that the new
treatment should be adopted as the new standard for all
patients if statistical assessment of relevant time-to-
event HR is significantly better than the standard control
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article, unless otherwise stated.However, this is a false assumption, as the value of a
HR can arise from numerous scenarios. For example a
HR of 0.75 will be generated if, in an RCT:
 the survival of all patients in the new treatment
group is increased by 25%, or
 25% of patients in the new treatment group
experience an approximate 3-fold survival benefit,
but the remaining 75% have no survival benefit, or
 25% of patients in the new treatment group
experience an approximate 4-fold survival benefit,
but the remaining 75% experience a 10% detriment,
This creates a major dilemma, as it appears impossible
to tease out the components of a HR, and distinguish
which new treatments should be introduced into routine
clinical practice for all patients, and which might actu-
ally be detrimental to the majority of patients. None of
the possible solutions seem to help: modeling suggests
that the survival plots resulting from these various sce-
narios are virtually indistinguishable, this uncertainty is
not ameliorated by increasing the sample size (thus
meta-analyses are equally unhelpful), and if predictive
factor analyses are undertaken and a subgroup of pa-
tients is found that benefits from the new treatment, it is
not possible to tell whether that subgroup in turn may
need to be subdivided further.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Stephens and Stewart BMC Cancer 2014, 14:260 Page 2 of 2
http://www.biomedcentral.com/1471-2407/14/260Outcomes such as response can identify the impact of
treatment on individual patients, but simply comparing
the numbers of patients who respond in an RCT does
not overcome the underlying problems, as:
 the RCT alone does not tell us which specific patient
subgroups benefit
 different subgroups of patients may benefit from
different treatments,
 response rates of combination therapy cannot
differentiate between the effectiveness of the
individual drugs.
Stewart and Kurzrock [1] have highlighted many of
the problems with RCTs in trying to identify ‘who bene-
fits?’ and argued that we need to identify predictive bio-
markers for response in phase I and II studies, and use
this information to enrich RCTs. Whilst this increases
the chances of a clearer outcome, it does not guarantee
that all patients will benefit, and does not negate the
need to explore other factors over and above the target
biomarker. Indeed, if a clear benefit is found in phase I
and II studies, there seems little point in running a large
expensive RCT.
Summary
As it is widely acknowledged that the future lies in indi-
vidualizing treatment, whether it be with new targeted
agents or chemotherapy, now may be the time to stand
up and expose the RCT and the HR as being as ineffect-
ive as the Emperor’s New Clothes in this pursuit, as their
past use may have contributed to us discarding many
useful treatments, or giving many patients suboptimal
treatment. Instead we need to concentrate on the use of
predictive factor analyses to identify the characteristics
of subgroups of patients who respond to specific treat-
ments. This would require identifying and collating ex-
tensive baseline clinical and biological data (from within
or outwith RCTs and/or audits) from large numbers of
patients who have received the same treatment, perhaps
relegating RCTs to a role of supplementary analyses if
different treatments appear to give similar response rates
in similar subgroups of patients.
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